Hints and tips:
Related Special Reports
...Talking with him is like speaking to a conscientious postdoctoral researcher who feels the need to substantiate his arguments with research and data....
...Another of his research interests is investigating the process by which simple molecules started to assemble into the first living organisms....
...Such “transferable exclusivity vouchers” could be applied to other drugs in their portfolios....
...The university has not applied for any fresh donations since 2019....
...The crunchy acronym was coined by Goldman Sachs for pharma companies GSK and Roche, Dutch chip company ASML, Switzerland’s Nestlé and Novartis, Danish drugmaker Novo Nordisk, France’s L’Oréal and LVMH, the...
...Shares in the French pharma company are struggling to recover from their steep fall in October....
...Shares in Sanofi fell 19 per cent on Friday after the French pharmaceutical group announced a lower profit outlook and a spinout of its consumer care unit as it seeks to focus on drug research....
...Roche said Telavant’s drug, known as RVT-3101, had the potential to be applied to conditions beyond IBD because the antibody tackles both inflammation and fibrosis....
...Some of the drugs will be injected into or under the skin, while others are applied as a topical gel....
...The company added in a statement that German law applied to the restructuring and “the terms and conditions of the bonds remain valid regardless of the decision”....
...However, the company’s big recent launches — including Dupixent, Altuviiio and Beyfortus — were done in partnership with other pharma companies, and the perception among many investors is that Sanofi does...
...BMS argues much of the progress in the fight against cancer is the result of post-approval research on small molecule drugs for patients....
...Eli Lilly has applied for regulatory approval to use its diabetes drug Mounjaro to treat obesity....
...The deal is a good fit for Sanofi, even though boss Paul Hudson pulled back from diabetes research in 2019....
...Passive problem Research bolsters the view that passive investment strategies are undermining the efficient markets hypothesis, the FT’s Katie Martin writes....
...Kering has a record of building up smaller brands such as Alexander McQueen and Bottega Veneta, a playbook that could be applied here — although the amount of control it can assert will be limited in the...
..., Professor, Department of Applied Health Research, University College London, London WC1, UK...
...Although it is a complex and expensive procedure, McGill believes it can be simplified and costs reduced when applied to autoimmune disease....
...Currently, the US receives 68 per cent of global biotech investment, according to the industry group Bio, and half of the top 20 biggest spenders on pharma research and development last year were American...
...Hudson is making strategic changes at the group that include exiting commodity categories such as heart disease and diabetes and pouring money into research into immunology and cancer....
...John Reed, Sanofi’s head of research and development, said in a statement that cancer treatments remain “a priority area for Sanofi”....
...Companies such as Samsung, Nvidia, Qualcomm, Broadcom, Texas Instruments, GlobalFoundries, ADI, ASML, NXP, Infineon, STMicroelectronics, Lam Research, Applied Materials and BASF declined to respond, or directed...
...One man with a near-perfect credit score applied for a £15,000 personal loan with an APR of 3.3 per cent, but was given a rate of 7.8 per cent, pushing up the cost of his monthly repayments....
...BNP Paribas said the collateral basket was “ESG compliant” because it applied its “sustainable policies” to the stock selection process and “stocks with the poorest ESG scores” were excluded....
...In its annual report published on Friday, GSK’s board said it had applied “clawback provisions” under its recoupment policy....
International Edition